Transporter-Based Drug–Drug Interactions and Their Effect on Distribution Volumes

Chapter

Abstract

Recently, drug transporters have emerged as significant modifiers of a patient’s pharmacokinetics. In cases where the functioning of drug transporters is altered, such as by drug–drug interactions, the resulting change in volume of distribution can lead to a significant change in drug effect or likelihood of toxicity, as well as a change in half-life independent of a change in clearance. Here, we discuss pharmacokinetic interactions at the transporter level that have been investigated in animals and humans and reported in literature, with a focus on the changes in distribution volume. Trends are discussed as they may be used to predict volume changes given the function of a transporter and the primary location of the interaction.

Keywords

Metformin Digoxin Tacrolimus Verapamil Simvastatin 

References

  1. Bajcetic M, Benndorf RA, Appel D, Schwedhelm E, Schulze F, Riekhof D, Maas R and Boger R (2007) Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. J Clin Pharmacol 47:295–304.CrossRefPubMedGoogle Scholar
  2. Bauer LA, Black DJ, Lill JS, Garrison J, Raisys VA and Hooton TM (2005) Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances. Antimicrob Agents Chemother 49:1649–1651.CrossRefPubMedGoogle Scholar
  3. Booth CL, Brouwer KR and Brouwer KL (1998) Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res 58:3641–3648.PubMedGoogle Scholar
  4. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N and Klaassen CD (2002) Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30:838–844.CrossRefPubMedGoogle Scholar
  5. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P and Schellens JH (2004) Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug–drug interactions. Cancer Res 64:5804–5811.CrossRefPubMedGoogle Scholar
  6. Brown G, Zemcov SJ and Clarke AM (1993) Effect of probenecid on cefazolin serum concentrations. J Antimicrob Chemother 31:1009–1011.CrossRefPubMedGoogle Scholar
  7. Carr RA, Pasutto FM and Foster RT (1996) Influence of cimetidine coadministration on the pharmacokinetics of sotalol enantiomers in an anaesthetized rat model: evidence supporting active renal excretion of sotalol. Biopharm Drug Dispos 17:55–69.CrossRefPubMedGoogle Scholar
  8. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y and Endou H (2000) Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 275:4507–4512.CrossRefPubMedGoogle Scholar
  9. Cherrington NJ, Hartley DP, Li N, Johnson DR and Klaassen CD (2002) Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97–104.CrossRefPubMedGoogle Scholar
  10. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG and Jang IJ (2005) Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78:342–350.CrossRefPubMedGoogle Scholar
  11. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P and Housman DE (1989) The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9:1346–1350.PubMedGoogle Scholar
  12. Desrayaud S, Guntz P, Scherrmann JM and Lemaire M (1997) Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci 61:153–163.CrossRefPubMedGoogle Scholar
  13. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G and Haefeli WE (2004) Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 76:73–84.CrossRefPubMedGoogle Scholar
  14. Dresser MJ, Leabman MK and Giacomini KM (2001) Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 90:397–421.CrossRefPubMedGoogle Scholar
  15. Grover A and Benet LZ (2009) Effects of drug transporters on volume of distribution. AAPS J 11:250–261.Google Scholar
  16. Guyton AC and Hall JE (2006) Textbook of Medical Physiology, Elsevier Saunders, Philadelphia.Google Scholar
  17. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–665.CrossRefPubMedGoogle Scholar
  18. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800–807.PubMedGoogle Scholar
  19. Inotsume N, Nishimura M, Nakano M, Fujiyama S and Sato T (1990) The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J Clin Pharmacol 30:50–56.PubMedGoogle Scholar
  20. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG and Schunack W (1995) Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 58:532–541.CrossRefPubMedGoogle Scholar
  21. Jette L, Beaulieu E, Leclerc JM and Beliveau R (1996) Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 270:F756–765.PubMedGoogle Scholar
  22. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ and Backman JT (2005) Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 78:388–399.CrossRefPubMedGoogle Scholar
  23. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ and Kaye SB (1986) The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 18:239–242.CrossRefPubMedGoogle Scholar
  24. Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P and Endou H (2003) Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol 465:1–7.CrossRefPubMedGoogle Scholar
  25. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H and Yamamoto T (2002) Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol 62:7–14.CrossRefPubMedGoogle Scholar
  26. Kugler AR, Olson SC and Smith DE (1996) Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: effect of organic anions and cations. J Pharmacokinet Biopharm 24:349–368.CrossRefPubMedGoogle Scholar
  27. Kunihara M, Nagai J, Murakami T and Takano M (1998) Renal excretion of rhodamine 123, a P-glycoprotein substrate, in rats with glycerol-induced acute renal failure. J Pharm Pharmacol 50:1161–1165.PubMedGoogle Scholar
  28. Lam JL, Shugarts SB, Okochi H and Benet LZ (2006) Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther 319:864–870.CrossRefPubMedGoogle Scholar
  29. Lau YY (2006) Examining the Regulation of Hepatic Drug Disposition and Metabolism by Organic Anion Transporting Peptide, P-Glycoprotein, and Multidrug Resistance-Associated Protein 2 [dissertation], University of California, San Francisco.Google Scholar
  30. Lau YY, Huang Y, Frassetto L and Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204.CrossRefPubMedGoogle Scholar
  31. Lin JH, Los LE, Ulm EH and Duggan DE (1988) Kinetic studies on the competition between famotidine and cimetidine in rats. evidence of multiple renal secretory systems for organic cations. Drug Metab Dispos 16:52–56.PubMedGoogle Scholar
  32. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer HH and Kuhlmann J (1999) Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65:251–261.CrossRefPubMedGoogle Scholar
  33. Nakashima E and Benet LZ (1988) General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 16:475–492.CrossRefPubMedGoogle Scholar
  34. Nakashima M, Uematsu T, Kosuge K, Okuyama Y, Morino A, Ozaki M and Takebe Y (1994) Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J Clin Pharmacol 34:930–937.PubMedGoogle Scholar
  35. Nooter K, Oostrum R and Deurloo J (1987) Effects of verapamil on the pharmacokinetics of daunomycin in the rat. Cancer Chemother Pharmacol 20:176–178.CrossRefPubMedGoogle Scholar
  36. Oh YH and Han H (2006) Pharmacokinetic interaction of tetracycline with non-steroidal anti-inflammatory drugs via organic anion transporters in rats. Pharmacol Res 53:75–79.CrossRefPubMedGoogle Scholar
  37. Øie S (1986) Drug distribution and binding. J Clin Pharmacol 26:583–586.PubMedGoogle Scholar
  38. Pasanen MK, Fredrikson H, Neuvonen PJ and Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726–733.CrossRefPubMedGoogle Scholar
  39. Pavlova A, Sakurai H, Leclercq B, Beier DR, Yu AS and Nigam SK (2000) Developmentally regulated expression of organic ion transporters NKT (OAT1), OCT1, NLT (OAT2), and roct. Am J Physiol Renal Physiol 278:F635–643.PubMedGoogle Scholar
  40. Sahin S and Benet LZ (2008) The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 25:2869–2877.CrossRefPubMedGoogle Scholar
  41. Sakurai Y, Motohashi H, Ogasawara K, Terada T, Masuda S, Katsura T, Mori N, Matsuura M, Doi T, Fukatsu A and Inui K (2005) Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm Res 22:2016–2022.CrossRefPubMedGoogle Scholar
  42. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455–463.CrossRefPubMedGoogle Scholar
  43. Sekine T, Cha SH and Endou H (2000) The multispecific organic anion transporter (OAT) family. Pflugers Arch 440:337–350.CrossRefPubMedGoogle Scholar
  44. Shiga T, Hashiguchi M, Urae A, Kasanuki H and Rikihisa T (2000) Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther 67:222–228.CrossRefPubMedGoogle Scholar
  45. Shitara Y, Horie T and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425–446.CrossRefPubMedGoogle Scholar
  46. Shitara Y, Sato H and Sugiyama Y (2005) Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689–723.CrossRefPubMedGoogle Scholar
  47. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM and Giacomini KM (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273–280.CrossRefPubMedGoogle Scholar
  48. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167–177.CrossRefPubMedGoogle Scholar
  49. Somogyi A, McLean A and Heinzow B (1983) Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol 25:339–345.CrossRefPubMedGoogle Scholar
  50. Speeg KV, Maldonado AL, Liaci J and Muirhead D (1992) Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology 15:899–903.CrossRefPubMedGoogle Scholar
  51. Su Y, Hu P, Lee SH and Sinko PJ (2007) Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. J Pharm Pharmaceut Sci 10:519–536.Google Scholar
  52. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR and Nigam SK (2002) Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem 277:26934–26943.CrossRefPubMedGoogle Scholar
  53. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y and Miki T (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19:375–380.CrossRefPubMedGoogle Scholar
  54. Tahara H, Kusuhara H, Chida M, Fuse E and Sugiyama Y (2006) Is the monkey an appropriate animal model to examine drug–drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther 316:1187–1194.CrossRefPubMedGoogle Scholar
  55. Tanaka Y, Slitt AL, Leazer TM, Maher JM and Klaassen CD (2005) Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326:181–187.CrossRefPubMedGoogle Scholar
  56. Tavoloni N and Guarino AM (1980) Biliary and urinary excretion of adriamycin in anesthetized rats. Pharmacology 20:256–267.CrossRefPubMedGoogle Scholar
  57. Tsuruoka S, Ioka T, Wakaumi M, Sakamoto K, Ookami H and Fujimura A (2006) Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther 79:389–396.CrossRefPubMedGoogle Scholar
  58. Ullrich K (1999) Affinity of drugs to the different renal transporters for organic anions and organic cations, in Membrane Transporters as Drug Targets (Amidon GL and Sadee W eds) pp 159–179, Kluwer Academic/Plenum Publishers, New York.Google Scholar
  59. van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJ and Pinedo HM (1990) Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1:56–64.PubMedGoogle Scholar
  60. van Giersbergen PL, Bodin F and Dingemanse J (2002) Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. Eur J Clin Pharmacol 58:243–245.CrossRefPubMedGoogle Scholar
  61. VanWert AL, Bailey RM and Sweet DH (2007) Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am J Physiol 293:F1332–F1341.CrossRefGoogle Scholar
  62. Wang Q, Yang H, Miller DW and Elmquist WF (1995) Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun 211:719–726.CrossRefPubMedGoogle Scholar
  63. Wu C-Y (2003) The Interactive Roles of P-glycoprotein and Cytochrome P-450 3A in Intestinal and Hepatic Drug Disposition [dissertation], University of California, San Francisco.Google Scholar
  64. Yagi Y, Aoki M, Iguchi M, Shibasaki S, Kurosawa T, Kato Y and Tsuji A (2007) Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats. Drug Metab Pharmacokinet 22:350–357.CrossRefPubMedGoogle Scholar
  65. Yagi Y, Shibutani S, Hodoshima N, Ishiwata K, Okudaira N, Li Q, Sai Y, Kato Y and Tsuji A (2003) Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin. Drug Metab Pharmacokinet 18:381–389.CrossRefPubMedGoogle Scholar
  66. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z and Sugiyama Y (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247–1254.CrossRefPubMedGoogle Scholar
  67. Yates JW and Arundel PA (2008a) Oral and IV dosing: a method to determine the compartment of drug elimination for two-compartment models. J Pharm Sci 97:2036–2040.CrossRefPubMedGoogle Scholar
  68. Yates JW and Arundel PA (2008b) On the volume of distribution at steady state and its relationship with two-compartmental models. J Pharm Sci 97:111–122.CrossRefPubMedGoogle Scholar
  69. Yesair DW, Schwartzbach E, Shuck D, Denine EP and Asbell MA (1972) Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Res 32:1177–1183.PubMedGoogle Scholar
  70. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, Miyamoto K and Tsuji A (1999) P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res 16:1213–1218.CrossRefPubMedGoogle Scholar
  71. Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X and Stewart CF (1998) Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J Pharmacol Exp Ther 284:89–94.PubMedGoogle Scholar
  72. Zheng HX, Huang Y, Frassetto LA and Benet LZ (2009) Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 85:78–85.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Biopharmaceutical SciencesUniversity of CaliforniaSan FranciscoUSA
  2. 2.Department of Biopharmaceutical SciencesUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations